InflaRx N.V.(IFRX)

$2.47▲0.03 (1.23%)

Chart

InflaRx N.V.(IFRX)

NASDAQ

$2.47▲0.03 (1.23%)

Chart Studio

IFRX(IFRX)

IFRX

Overview Intelligence Chart History Fundmntls TTM Earnings Growth Analysts News Financials Insiders Institl.DCF Peers

IFRX 50 articles

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

seekingalpha.com·May 8

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

marketbeat.com·May 8

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

globenewswire.com·May 8

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

globenewswire.com·May 6

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

globenewswire.com·May 6

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

globenewswire.com·May 4

InflaRx to Report First Quarter 2026 Results on May 7, 2026

globenewswire.com·May 1

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

globenewswire.com·Apr 28

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

globenewswire.com·Apr 9

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

globenewswire.com·Mar 31

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

globenewswire.com·Mar 30

InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Analysts

defenseworld.net·Mar 30

Reviewing Athira Pharma (NASDAQ:ATHA) & InflaRx (NASDAQ:IFRX)

defenseworld.net·Mar 27

InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates

zacks.com·Mar 19

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

globenewswire.com·Mar 19

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

globenewswire.com·Mar 18

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

globenewswire.com·Mar 13

InflaRx to Report Full Year 2025 Results on March 19, 2026

globenewswire.com·Mar 12

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

globenewswire.com·Feb 26

InflaRx Announces Participation in February Investor Conferences

globenewswire.com·Jan 29

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts

defenseworld.net·Jan 11

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

globenewswire.com·Jan 8

InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

feeds.benzinga.com·Jan 5

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

globenewswire.com·Dec 30

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

globenewswire.com·Dec 11

InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript

seekingalpha.com·Nov 10

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

globenewswire.com·Nov 10

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

globenewswire.com·Nov 7

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

globenewswire.com·Oct 21

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

globenewswire.com·Sep 12

InflaRx Announces Participation in September Investor Conferences

globenewswire.com·Aug 21

InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

zacks.com·Aug 7

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

globenewswire.com·Aug 7

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

globenewswire.com·Jul 31

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

globenewswire.com·Jul 11

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

benzinga.com·May 28

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

globenewswire.com·May 28

InflaRx to Participate in Upcoming Investor Conferences

globenewswire.com·May 22

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

globenewswire.com·May 7

InflaRx to Report First Quarter 2025 Results on May 7, 2025

globenewswire.com·Apr 30

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

zacks.com·Mar 26

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

globenewswire.com·Mar 20

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

globenewswire.com·Mar 7

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

globenewswire.com·Feb 28

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

globenewswire.com·Feb 25

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

globenewswire.com·Feb 18

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

globenewswire.com·Feb 13

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

globenewswire.com·Feb 13

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

globenewswire.com·Jan 23

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

zacks.com·Jan 16

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance